Birchview Capital’s Nektar Therapeutics NKTR Stock Holding History

Birchview Capital’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.65M	Buy	81,000 +50,000	+161%	+$3.66M	2.64%	9
2026 Q1	$2.23M	Hold	31,000	–	–	1.27%	19
2025 Q4	$1.31M	Buy	31,000 +26,979	+671%	+$1.51M	0.77%	34
2025 Q3	$229K	Buy	+4,021	New	+$133K	0.17%	62
2023 Q4	–	Sell	-1,867	Closed	-$16.7K	–	59
2023 Q3	$16.7K	Hold	1,867	–	–	0.01%	50
2023 Q2	$16.1K	Sell	1,867 -6,000	-76%	-$64K	0.01%	54
2023 Q1	$83K	Hold	7,867	–	–	0.07%	52
2022 Q4	$267K	Sell	7,867 -666	-8%	-$32.2K	0.19%	45
2022 Q3	$410K	Hold	8,533	–	–	0.29%	41
2022 Q2	$486K	Hold	8,533	–	–	0.35%	38
2022 Q1	$690K	Buy	8,533 +1,866	+28%	+$276K	0.5%	35
2021 Q4	$1.35M	Buy	6,667 +1,867	+39%	+$405K	0.87%	22
2021 Q3	$1.29M	Hold	4,800	–	–	0.88%	24
2021 Q2	$1.24M	Sell	4,800 -1,333	-22%	-$369K	0.74%	23
2021 Q1	$1.84M	Buy	+6,133	New	+$1.91M	1.09%	16
2019 Q3	–	Sell	-633	Closed	-$338K	–	54
2019 Q2	$338K	Hold	633	–	–	0.21%	38
2019 Q1	$319K	Hold	633	–	–	0.2%	41
2018 Q4	$312K	Hold	633	–	–	0.3%	35
2018 Q3	$579K	Hold	633	–	–	0.37%	29
2018 Q2	$464K	Buy	+633	New	+$730K	0.32%	32

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Birchview Capital's NKTR Position: Q2 2026 in Review

Birchview Capital increased its Nektar Therapeutics (NKTR) stake by 161% in Q2 2026, buying an estimated $3.66M and bringing the position to 81,000 shares worth $5.65M. The position accounts for 2.64% of the portfolio, ranked #9.

Birchview Capital first reported a position in NKTR in Q2 2018 and has held it in 20 quarters since. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

Birchview Capital held 81,000 shares of Nektar Therapeutics worth $5.65M as of Q2 2026.
Birchview Capital bought 50,000 Nektar Therapeutics shares in Q2 2026, an estimated $3.66M.
Nektar Therapeutics made up 2.64% of Birchview Capital's portfolio in Q2 2026, its #9 holding.
Birchview Capital first reported a position in Nektar Therapeutics in Q2 2018 and has held it in 20 quarters since.
240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.